PD-L1 Expression Is Associated with Tumor FOXP3⁺ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient

Abstract

Background: Expression of PD-L1 has been estimated to predict the therapeutic potential of PD-L1 inhibition in solid tumors. Recent studies have demonstrated that PD-L1 plays a critical role in regulatory T-cell (Treg) development and functional maintenance. Although increases in FOXP3+Treg infiltration and PD-L1 expression have been revealed in several malignancies, their correlation in human breast tumors is as yet unclear.Methods: Whole-tissue sections from 501 patients with breast cancer were examined for PD-L1 and FOXP3 expression by immunohistochemistry. Correlation between their expressions and the association with clinicopathological features, intrinsic tumor subtypes and patient's prognosis were studied.Results: PD-L1 expression and FOXP3+Treg infiltrates in tumor tissue demonstrated a high correlation (rs=0.334, p<0.001) in this cohort of breast cancer patients. High PD-L1 expression and increased FOXP3+Treg infiltrates were both associated with high histological grade, negative ER and PR status, and aggressive intrinsic tumor subtypes, especially the basal-like subtype. Tumors with concomitant high expressions of the two markers had the worst prognosis. Multivariate analysis proved both markers to be the independent predictors for decreased overall survival of patients, particularly in the basal-like subtype.Conclusions: The results suggest that PD-L1 and FOXP3+Tregs may work synergistically and their up-regulated expressions promote tumor immune evasion in breast cancer. Combinatorial immunotherapeutic approaches aiming on blocking PD-L1 and depleting Tregs might improve therapeutic efficacy in breast cancer patients, especially those with basal-like carcinoma.

Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma

“…However, FOXP3-positive Tregs42 43 are able to suppress immune attack against tumour cells by inhibiting CD4, CD8, natural killer (NK) cell, B cell and antigen-presenting cell function 44 45. FOXP3 counts have additionally been shown to work synergistically with programmed death-ligand 1 (PDL1),46 which is induced in EBV-positive NPC by latent membrane protein 1 (LMP1) through oncogenic pathways and immune modulation 47. Thus, FOXP3-positive Tregs are hypothetically associated with poor prognosis, and thus contradicting the results of this study.…”

PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer

“…Thus, it plays an important role in dampening the T cell mediated anti-tumor immune response [1,2]. Numerous studies have shown that many human cancers display PD-L1 over-expression, and that its expression is significantly associated with patients' clinical parameters and postoperative prognoses [3][4][5]. In addition, multiple clinical studies have demonstrated that PD-L1 blockade can significantly inhibit tumor progression and improve patient prognosis in many advanced cancers, including melanoma, gastric cancer, non-small-cell lung cancer, ovarian cancer, renal cell cancer and so on.…”

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells

“…[100] High levels of Treg cells correlate with cancer progression and poor patient prognosis. [101, 102] Most studies using NPs loaded with drugs, small molecules, oligonucleotides, immunomodulatory compounds, etc. have not directly targeted Treg cells but have indirectly decreased or increased Treg cell levels.…”